ENTO Stock Overview A clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Entero Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Entero Therapeutics Historical stock prices Current Share Price US$0.50 52 Week High US$9.35 52 Week Low US$0.18 Beta 0.97 1 Month Change -15.24% 3 Month Change -20.63% 1 Year Change -89.98% 3 Year Change -99.99% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Entero Therapeutics, Inc. Announces Board Changes Feb 08
Less than half of directors are independent Nov 15 Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction. Nov 13
Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2) Sep 12
Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q Aug 25 Entero Therapeutics, Inc. announced delayed 10-Q filing Aug 16
See more updates
Entero Therapeutics, Inc. Announces Board Changes Feb 08
Less than half of directors are independent Nov 15 Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction. Nov 13
Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2) Sep 12
Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q Aug 25 Entero Therapeutics, Inc. announced delayed 10-Q filing Aug 16
Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2) Aug 08
First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index May 18 First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million. May 11
First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million. Mar 15
First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million. Mar 14
First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million. Mar 04
First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering. Dec 29
First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC. Dec 19
First Wave BioPharma, Inc. has filed a Follow-on Equity Offering. Nov 04
First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market Nov 01
First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Aug 27
First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1) Aug 21
First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation Jul 14
New major risk - Share price stability Jun 14
First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis May 12
First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement Feb 08
First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis Feb 03
First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis Feb 01
First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio Jan 26
First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency Jan 14
First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price Dec 17
First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase Dec 06
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase Dec 02
First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360 Oct 11 First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million. Oct 07
First Wave BioPharma announces pricing of $6.0 million public offering Oct 07
First Wave BioPharma, Inc. Provides Update on Clinical Programs Sep 20
First Wave BioPharma extends selloff after announcing strategic shift Sep 19
First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation Sep 08
First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase Sep 07
First Wave BioPharma Announces Reverse Stock Split Aug 27
First Wave BioPharma announces 1-for-30 reverse stock split Aug 25
Price target decreased to US$9.00 Aug 17
High number of new and inexperienced directors Aug 17
First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022 Jul 19
First Wave BioPharma to raise capital in convertible preferred stocks offering Jul 15
First Wave Biopharma, Inc Announces Resignation from the Board of Directors Jun 19 First Wave BioPharma, Inc. announced delayed 10-Q filing
First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board May 02
Price target decreased to US$20.00 Apr 27
High number of new and inexperienced directors Apr 27
James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc Apr 07
First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19 Mar 29 First Wave Biopharma, Inc. Announce Chief Financial Officer Changes
First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program Jan 14
First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections Jan 07
High number of new directors Jan 03
First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC Nov 30
First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment Oct 19
First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis Oct 01
Price target decreased to US$25.00 Sep 17
AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million. Sep 15
AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Sep 10
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis Sep 09
No longer forecast to breakeven Aug 19
AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency Aug 19
AzurRx BioPharma Inc Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Aug 13
Azurrx Biopharma, Inc. Adds New Clinical Trial Sites in Ukraine for Phase 2 Reservoir Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections Aug 12
AzurRx BioPharma Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Jun 19
AzurRx BioPharma, Inc. Doses First Patient in Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections Jun 08
AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study Jun 07
AzurRx BioPharma, Inc. announced delayed 10-Q filing May 19
AzurRx BioPharma, Inc. Announces Positive Interim Data in Phase 2 Clinical Trial of Ms1819 in Combination with Pert in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency May 14
AzurRx BioPharma: An Assessment May 02
AzurRx BioPharma, Inc. Announces Completion of Enrollment in Phase 2B Option 2 Clinical Trial of Ms1819 in Cystic Fibrosis Mar 17
AzurRx BioPharma, Inc. Announces Chairman Changes Feb 25
Price target raised to US$4.10 Feb 11
AzurRx Biopharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections Feb 10 Shareholder Returns ENTO US Biotechs US Market 7D -7.4% -1.3% 1.2% 1Y -90.0% -4.5% 21.0%
See full shareholder returns
Return vs Industry: ENTO underperformed the US Biotechs industry which returned -4.5% over the past year.
Return vs Market: ENTO underperformed the US Market which returned 21% over the past year.
Price Volatility Is ENTO's price volatile compared to industry and market? ENTO volatility ENTO Average Weekly Movement 17.8% Biotechs Industry Average Movement 11.5% Market Average Movement 6.0% 10% most volatile stocks in US Market 18.5% 10% least volatile stocks in US Market 3.0%
Stable Share Price: ENTO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ENTO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company’s pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients.
Show more Entero Therapeutics, Inc. Fundamentals Summary How do Entero Therapeutics's earnings and revenue compare to its market cap? ENTO fundamental statistics Market cap US$2.38m Earnings (TTM ) -US$8.15m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ENTO income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$8.15m Earnings -US$8.15m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/11 00:35 End of Day Share Price 2025/02/11 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Entero Therapeutics, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null Argus Research Company Jonathan Aschoff B. Riley Wealth Leland Gershell Oppenheimer & Co. Inc.
Show 2 more analysts 
